Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia
Journal
Leukemia and Lymphoma
Journal Volume
54
Journal Issue
8
Pages
1614-1625
Date Issued
2013
Author(s)
Yang W.-C.
Lin P.-M.
Yang M.-Y.
Liu Y.-C.
Chang C.-S.
Hsu J.-F.
Huang C.-T.
Cho S.-F.
Yu W.-H.
Lin S.-F.
Abstract
Several molecular markers, such as NPM1, FLT3 and CEBPA, have been incorporated into both the World Health Organization and European LeukemiaNet classifications as routine assessments for the diagnosis and evaluation of prognostic significance in acute myeloid leukemia (AML). Lipocalin 2 (LCN2) is related to cancer development and is believed to be associated with the outcome of cytogenetically normal (CN)-AML. In the present study, we analyzed the prognostic effects and interactions of LCN2 expression (by molecular analysis, quantitative real-time polymerase chain reaction [qRT-PCR]) with neucleophosmin 1, fms-related tyrosine kinase 3 (FLT3) and CCAAT/enhancer-binding protein alpha mutations in 85 patients with CN-AML receiving intensive induction chemotherapy. Our results indicate that patients with higher LCN2 mRNA expression in the bone marrow (LCN2high), especially in combination with wild type FLT3-ITD, had better prognoses. FLT3-ITD compensated LCN2-overexpression- enhanced oxidative stress-induced apoptosis in cell line studies. In conclusion, LCN2high was associated with better prognosis, and FLT3 status had an adjuvant effect on overall survival. ? 2013 Informa UK, Ltd.
SDGs
Other Subjects
CCAAT enhancer binding protein alpha; CD135 antigen; cytarabine; daunorubicin; messenger RNA; neutrophil gelatinase associated lipocalin; nucleophosmin; acute granulocytic leukemia; adult; aged; allogeneic peripheral blood stem cell transplantation; article; bone marrow; cancer chemotherapy; cancer prognosis; cancer survival; cell differentiation; controlled study; cytogenetics; female; gene expression; gene mutation; gene overexpression; genetic analysis; human; human cell; induction chemotherapy; leukemia cell line; major clinical study; male; overall survival; priority journal; protein expression; protein interaction; quantitative analysis; real time polymerase chain reaction; treatment duration; wild type; Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Case-Control Studies; CCAAT-Enhancer-Binding Proteins; Cell Line; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Gene Expression Regulation, Leukemic; Humans; Karyotype; Leukemia, Myeloid, Acute; Lipocalins; Male; Middle Aged; Mutation; Nuclear Proteins; Prognosis; Proto-Oncogene Proteins; RNA, Messenger; Young Adult
Type
journal article